泽璟制药注射用ZG006开展关键性临床试验并完成首例受试者入组

Core Viewpoint - ZaiJing Pharmaceutical has received feedback from the National Medical Products Administration (NMPA) regarding the conditional approval for the clinical trial of its investigational drug ZG006, indicating progress in its development [1] Group 1: Product Development - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [1] - The drug has received clinical trial approval from both the US FDA and China's NMPA, and has been designated as a breakthrough therapy by the NMPA and granted orphan drug status by the FDA [1] Group 2: Clinical Trials - The NMPA has agreed to allow ZG006 to proceed with critical clinical trials based on current safety and efficacy data and the proposed target population [1] - The company is actively advancing the critical clinical trials for ZG006 and has recently completed the enrollment of the first subject [1]